Sarepta Therapeutics is still assessing how best to prevent liver injury from its commercialized Duchenne muscular dystrophy gene therapy. But Sarepta partner Hansa Biopharma has encouraging preliminary data from a small clinical study suggesting its organ transplant rejection drug could find an additional use as a pretreatment option for Duchenne patients dosed with the gene therapy, Elevidys.

In three Duchenne patients who received one dose of the Hansa drug, imlifidase, the Lund, Sweden-based company reported a rapid reduction of immunoglobulin G (IgG) antibodies, which are antibodies that can drive excessive immune responses. Hansa said it will discuss with Sarepta the next steps for this program, currently in Phase 1 testing.

Elevidys is carried to muscle cells aboard an adeno-ass

See Full Page